Radiofrequency Ablation Multicenter Observational Study in Renal Oncology Patients
ConditionRenal Carcinoma
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorHumanitas Hospital, Italy
About this trial
This observational study is designed to expand the current database available in the literature and the existing knowledge on the outcomes and safety of radiofrequency ablation (RFA) for the treatment of primary renal cell carcinomas in stage T1a. All interventions and subsequent follow-ups are clinical decisions are independent of the study, given its observational nature.
Eligibility criteria
Qualifiers
Age ≥18 years
Signed informed consent approved by the Ethics Committee prior to the ablation procedure.
RCC in stage T1a (size <4 cm), single or multiple, histologically demonstrated by percutaneous biopsy before or within 30 days prior to ablation
Absence of comorbidities that contraindicate treatment
Disqualifiers
No specific exclusion criteria are established for this clinical registry due to its observational nature. Each center will apply its own criteria according to its routine clinical practice.
Trial design
Treatments tested in this trial
- Radiofrequency Ablation (RFA)
Treatment groups
No treatment groups listed
Sponsors and collaborators
Humanitas Hospital, Italy
Lead sponsor
SACMI-Sociedad Aragonesa de Cirugìa Minimamante Invasiva
Collaborator
Source ClinicalTrials.gov